Inogen (NSDQ:INGN) this week announced that it has appointed Stanislav Glezer as executive VP and chief medical officer, effective June 21.
Glezer joins the Goleta, Calif.-based company after a stint as worldwide VP of medical care for diabetes care at BD. Prior to BD, he served as chief medical officer at Adocia and has held numerous leadership roles within Novo Nordisk and Sanofi.
“On behalf of the board of directors, I would like to congratulate Stan on this appointment as I am confident that he will be a tremendous asset to Inogen and a great addition to our executive team. I believe that expanding our clinical expertise and evidence dossier in respiratory therapy will serve us well in our endeavors to drive our market development efforts to eventually increase the penetration of portable oxygen concentrators (POCs) in support of our growth strategy as well as help guide our innovation agenda,” CEO Nabil Shabshab said in a news release. “I believe Stan’s over 25 years of experience in clinical research and medical affair roles with strong experience in commercial, market access and other areas across a variety of medical technology and biotechnology firms will be a great enabler in building a stronger Inogen and elevating our clinical capabilities overall.”
“I am honored by the opportunity to lead the medical affairs, clinical research, [and regulatory] organizations of Inogen in our mission to increase the freedom and independence for respiratory patients and to meaningfully improve clinical outcomes, as demonstrated by clinical evidence, generated in collaboration with health care practitioners and key opinion leaders in our effort to make our technologies the standard of care,” Glezer said. “I look forward to contributing to the next phase of Inogen’s planned growth as we continue to seek ways to design patient-centric outcomes studies to improve access to our best-in-class product offerings, enable prescribers to better serve their patients and enhance our market position and value for our stockholders.”